Inhibitex (INHX) gains 6.5% in premarket trading after reporting positive data from clinical...

|By:, SA News Editor

Inhibitex (INHX) gains 6.5% in premarket trading after reporting positive data from clinical tests of its INX-189 hepatitis C treatment and saying it plans to expand its testing to evaluate the effect of various doses. The company notes it will use the proceeds from a 1.9M common stock offering to help support its INHX-189 development in 2012.